Communicators

Pluristem Therapeutics to Present at the German Equity Forum

NEW YORK - Pluristem Therapeutics Inc. (NasdaqCM: PSTI; DAX: PJT), a bio-therapeutics company dedicated to the commercialization of unrelated donor-patient (allogeneic) cell therapy products for a variety of disorders, announced today that Zami Aberman, Chairman, President and CEO, has been invited by the Equity Forum in Stuttgart, Germany to present updates on the Company's corporate development in Germany and its Phase I clinical trials using the Company’s placental-derived stem cell product, PLX-PAD. Mr. Aberman will also discuss the arrangements with Charité – Universitätsmedizin Berlin and Franziskus-Krankenhaus Hospital for the upcoming Critical Limb Ischemia (CLI) clinical trials in Germany. The presentation, which is organized by the Deutsche Börse and the KfW SME Bank, will be held on April 29, 2009.

“Pluristem has established long term scientific collaborations with outstanding German institutions such as the Charité – Universitätsmedizin Berlin and the Fraunhofer Institute for Immunology and Cell Therapy in Liepzig”, stated Zami Aberman, Chairman, President and CEO of Pluristem. “We look forward to presenting our clinical trial’s progress, as well as the Company's future business plans, to the investment community at the Stuttgart Equity Forum”.

About the German Equity Forum

The German Equity Forum is one of the largest capital market conferences in Europe. The conference is organized by the Deutsche Börse and the KfW SME Bankengruppe. The Deutsche Börse is one of the world’s leading exchange organizations, which provides investors, financial institutions and companies access to global capital markets, while KfW Bankengruppe gives impetus to economic, social and ecological development worldwide and is a promotional bank under the ownership of the Federal Republic and the Länder (federal states).

About Pluristem

Pluristem Therapeutics Inc. is a bio-therapeutics company dedicated to the commercialization of unrelated donor-patient (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from human placenta, a non-controversial, non-embryonic, adult stem cell source.

These placental adherent stromal cells (ASCs) are expanded in the Company's proprietary PluriXTM 3D bioreactor, which imitates the natural 3D microenvironment of these cells and does not require supplemental growth factors or other exogenous materials. Pluristem believes that the resultant PLX (PLacental eXpanded) cells’ efficacy may be related to the secretion of cytokines or other potent immune modulators. Furthermore, PLX cells are immune privileged and possess immunomodulatory properties, thus protecting the recipient from immunological reactions that often accompany transplantations.

Pluristem's first product in development, PLX-PAD, is intended to improve the quality of life of millions of people suffering from peripheral artery disease (PAD). The Company's products in development also include PLX-IBD, targeting Inflammatory Bowel Disease (IBD); PLX-MS, targeting Multiple Sclerosis; PLX-BMT, targeting the global shortfall of matched tissue for bone marrow transplantation (BMT) by improving the engraftment of hematopoietic stem cells (HSCs) contained in umbilical cord blood; and PLX-STROKE, targeting ischemic stroke.

Pluristem has offices in the USA with research and manufacturing facilities in Israel.

See our product animation on YouTube: Animation

Safe Harbor Statement

This press release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, when we say that we will present our clinical trial’s progress, as well as the Company's future business plans, to the investment community at the Stuttgart Equity Forum, we are using forward-looking statements. These forward-looking statements are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risk and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.

For more information visit our website at www.pluristem.com, the content of which is not part of this press release.

Contact:

Pluristem Therapeutics Inc.
William Prather RPh, MD
Sr. VP Corporate Development
+1-303-883-4954
William.PratherMD@pluristem.com



NEWSLETTER REGISTRIERUNG:
Aktuelle Pressemeldungen dieses Unternehmens direkt in Ihr Postfach:
http://www.irw-press.com/alert_subscription.php?lang=en&isin=US72940R1023

Mitteilung übermittelt durch IRW-Press.com. Für den Inhalt ist der Aussender
verantwortlich.
Kostenloser Abdruck mit Quellenangabe erlaubt.